论文部分内容阅读
用同位素ａ－３２ＰｄＣＴＰ标记癌基因Ｃ－Ｈａ－ｒａｓ，Ｃ－ｍｙｃ和Ｖ－ｓｉｓ基因片段，通过点杂交和Ｓｏｕｔｈｅｒｎ杂交法检测１７例鳞癌，９例腺癌，６例其它类型肺癌组织和６例非肺癌组织中Ｃ－Ｈａ－ｒａｓ，Ｃ－ｍｙｃ和Ｃ－ｓｉｓ基因扩增的情况．结果发现：４６．８％（１５／３２）的肺癌组织有Ｃ－Ｈａ－ｒａｓ基因扩增，其中１０例（５８．８ ％）鳞癌，３例腺癌（３３．３ ％）出现Ｃ－Ｈａ－ｒａｓ基因扩增。２５％（８／３２）的肺癌组织中出现Ｃ－ｍｙｃ基因扩增，其中 ４例（２３．５％）鳞癌，３例（３３．３％）腺癌出现Ｃ－ｍｙｃ基因扩增。１８．８％（６／３２）的肺癌组织有Ｃ－ｓｉｓ基因扩增，其中４例（２３．５％）鳞癌，１例（１１．１％）腺癌出Ｃ－ｓｉｓ基因扩增。而６例非肺癌组织都役有这三种癌基因扩增。同时我们也发现有５例肺癌组织（４例鳞癌和１例腺癌）出现两种癌基因的扩增。上述结果提示：Ｃ－Ｈａ－ｒａｓ，Ｃ－ｍｙｃ和Ｃ－ｓｉｓ基因的扩增与肺癌的发生有关，特别是Ｃ－Ｈａ－ｒａｓ基因扩增在肺鳞癌的形成过程中可能起着重要作用。同时还提示：肺癌的发生与两种癌基因的扩增可能有一定关系。
The oncogene C-Ha-ras, C-myc and V-sis gene fragments were labeled with isotope a-32PdCTP. Seventeen squamous cell carcinomas, nine adenocarcinomas, six other types of lung cancer tissues and six were detected by spot hybridization and Southern hybridization. 2. Cases of non-lung cancer tissue amplification of C-Ha-ras, C-myc and C-sis genes. Results: 46.8% (15/32) of the lung cancer tissues had C-Ha-ras gene amplification, of which 10 (58.8 %) squamous cell carcinomas and 3 adenocarcinomas (33.3 %) showed C- Ha-ras gene amplification. C-myc gene amplification occurred in 25% (8/32) of lung cancer tissues, including 4 (23.5%) squamous cell carcinomas and 3 (33.3%) adenocarcinomas showing C-myc gene amplification. 18.8% (6/32) of the lung cancer tissues had C-sis gene amplification, of which 4 (23.5%) had squamous cell carcinoma and 1 (11.1%) had adenocarcinoma C-sis gene amplification. In contrast, 6 of the non-lung cancer tissues had the amplification of these three oncogenes. At the same time, we also found the amplification of two oncogenes in 5 lung cancer tissues (4 squamous cell carcinomas and 1 adenocarcinoma). These results suggest that the amplification of C-Ha-ras, C-myc and C-sis genes is associated with the development of lung cancer, especially the amplification of C-Ha-ras genes may play an important role in the formation of lung squamous cell carcinoma. . It also suggests that the occurrence of lung cancer may be related to the amplification of two oncogenes.